Trial Profile
Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sirolimus (Primary) ; Aspirin; Clopidogrel
- Indications Coronary artery disease; Coronary artery restenosis; Embolism and thrombosis; Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms EXCELLENT
- 30 Sep 2017 Results published in the Circulation Journal
- 16 Dec 2011 Results published in Circulation.
- 25 Oct 2011 Results published in the Journal of the American College of Cardiology.